Virtual Auricular Point Acupressure (APA) for Chemotherapy-Induced Neuropathy

Phase-Based Progress Estimates
Chemotherapy-Induced NeuropathyVirtual Auricular Point Acupressure (APA) - Device
All Sexes
What conditions do you have?

Study Summary

This trial will evaluate auricular point acupressure (APA) on chemotherapy-induced neuropathy (CIN), with the goal of understanding its efficacy and underlying mechanism(s).

Eligible Conditions
  • Chemotherapy-Induced Neuropathy

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 4 Secondary · Reporting Duration: Up to 4 months

Up to 1 month
Change of brain activity as assessed by fMRI Neuroimaging
Up to 4 months
Change in anti-inflammatory cytokines as assessed by serum cytokine biomarkers
Change in numbness as assessed by the Brief Pain Inventory
Change in pain severity as assessed by the Brief Pain Inventory
Change in physical function as assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) 29
Change in pro-inflammatory cytokines as assessed by serum cytokine biomarkers
Change in tingling as assessed by the Brief Pain Inventory
Change of pain sensitivity as assessed by Qualitative Sensory Testing (QST)

Trial Safety

Safety Progress

1 of 3

Trial Design

3 Treatment Groups

Usual Care Control
1 of 3
APA Group
1 of 3
Virtual APA group
1 of 3

Active Control

Experimental Treatment

240 Total Participants · 3 Treatment Groups

Primary Treatment: Virtual Auricular Point Acupressure (APA) · No Placebo Group · N/A

APA Group
Experimental Group · 1 Intervention: Virtual Auricular Point Acupressure (APA) · Intervention Types: Device
Virtual APA group
Experimental Group · 1 Intervention: In-Person Training · Intervention Types: Other
Usual Care Control
ActiveComparator Group · 1 Intervention: Usual Care · Intervention Types: Other
First Studied
Drug Approval Stage
How many patients have taken this drug
Virtual Auricular Point Acupressure (APA)

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 4 months

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,073 Previous Clinical Trials
31,016,985 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,070 Previous Clinical Trials
41,128,874 Total Patients Enrolled
M.D. Anderson Cancer CenterOTHER
2,802 Previous Clinical Trials
1,788,663 Total Patients Enrolled
University of TexasOTHER
173 Previous Clinical Trials
121,690 Total Patients Enrolled
Thomas Smith, MDPrincipal InvestigatorJohns Hopkins School of Medicine
2 Previous Clinical Trials
67 Total Patients Enrolled
Chao Hsing Yeh, PhDPrincipal InvestigatorJohns Hopkins School of Nursing
5 Previous Clinical Trials
606 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have one of the average intensity of pain, or numbness, or tingling on your extremities the previous week due to CIN ≥ 4 on a 11-point numerical scale.
You have cancer or pre-existing peripheral neuropathy of another etiology that worsened after chemotherapy.